By Reuters

Copyright reuters

SummaryCompaniesPfizer to pay $47.50/share for Metsera, plus up to $22.50 tied to milestones – FTDeal may be announced Monday, pending final talks – FTPfizer eyes anti-obesity market after setbacks

Sept 21 (Reuters) – Pfizer (PFE.N), opens new tab is closing in on a potential $7.3 billion takeover of weight-loss drug developer Metsera (MTSR.O), opens new tab, the Financial Times reported on Sunday, citing unidentified sources.

The U.S. pharma firm will acquire New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the newspaper said, adding that the announcement could come as early as Monday, unless deal talks fall through.

Advertisement · Scroll to continue

Reuters could not immediately confirm the report. Pfizer and Metsera did not immediately respond to a Reuters request for comment outside regular business hours.

Talks to acquire Metsera come just months after the biotech firm’s blockbuster Nasdaq debut, underscoring surging investor appetite for companies developing next-generation weight-loss therapies.

The $47.50-per-share bid marks a roughly 42.5% premium over Metsera’s Friday closing price of $33.32, which pegged its market value at about $3.5 billion, according to LSEG data.

The deal marks Pfizer’s latest bid to secure a foothold in the lucrative anti-obesity drug market, following setbacks in its own development efforts.

Advertisement · Scroll to continue

The company had been working on an experimental weight-loss pill, danuglipron, but abandoned the project in April after a mid-stage trial revealed poor tolerability. A once-daily extended-release version was later tested in roughly 1,400 patients, but persistent liver safety concerns further undermined the company’s ambitions.

Metsera, founded in 2022 by venture capital firm ARCH Venture and investment company Population Health Partners, is developing injectable and oral drugs to treat obesity, based on the GLP-1 mechanism and other biological targets.

Its lead candidate, MET-097i, an injectable, showed an average weight loss of 11.3% in patients during a mid-stage trial, the company said earlier this year.

Demand for weight-loss drugs is surging, with rivals Eli Lilly (LLY.N), opens new tab and Novo Nordisk (NOVOb.CO), opens new tab intensifying their battle for market dominance.

Ad Break Coming Up

NEXT StayNext

OffEnglish

180p288p360p480p540p576p720pHD1080pHDAuto (180p)

About ConnatixV2049621718
About ConnatixV2049621718

Continue watchingafter the adVisit Advertiser websiteGO TO PAGE

Some experts forecast that the global weight-loss drug market could be valued at $150 billion by the early 2030s.

Reporting by Mrinmay Dey in Bengaluru; Editing by Janane Venkatraman and Mrigank Dhaniwala

Purchase Licensing Rights